Extended release dosage form of glipizide: Development and validation of a level a in vitro-in vivo correlation

Biological and Pharmaceutical Bulletin

Volumn 31, Issue 10, 2008, Pages 1946-1951

  Ghosh, Animesh ^a   Bhaumik, Uttam Kumar ^a   Bose, Anirbandeep ^a   Mandal, Uttam ^a   Gowda, Veeran ^a   Chatterjee, Bappaditya ^a   Chakrabarty, Uday Sankar ^a   Pal, Tapan Kumar ^a  

^a JADAVPUR UNIVERSITY   (India)

Author keywords

Bioavailability; Controlled release; Dissolution; In vitro model; In vitro in vivo correlation

Indexed keywords

BUFFER; GLIPIZIDE; HYDROCHLORIC ACID; PHOSPHATE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG FORMULATION; DRUG RELEASE; DRUG SOLUBILITY; ERROR; EVALUATION; EXTENDED RELEASE FORMULATION; FAST RELEASE FORMULATION; HUMAN; HUMAN EXPERIMENT; IMMEDIATE RELEASE FORMULATION; IN VITRO IN VIVO CORRELATION; LINEAR REGRESSION ANALYSIS; MALE; MAXIMUM PLASMA CONCENTRATION; MODERATE RELEASE FORMULATION; NORMAL HUMAN; OPEN STUDY; PREDICTION; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; RELIABILITY; SINGLE DRUG DOSE; SLOW RELEASE FORMULATION; TIME TO MAXIMUM PLASMA CONCENTRATION; VALIDATION PROCESS;

ADULT; ALGORITHMS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CHEMISTRY, PHARMACEUTICAL; DELAYED-ACTION PREPARATIONS; GLIPIZIDE; HUMANS; HYPOGLYCEMIC AGENTS; LINEAR MODELS; MALE; REPRODUCIBILITY OF RESULTS; SOLUBILITY;

EID: 53549103905     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.31.1946     Document Type: Article

References (16)

1. "In Vitro In Vivo Evaluation of Dosage Forms," United States of Pharmacopeia XXIII chapter, United States Pharmacopeial Convention, Incorporated, Rockville, Maryland, 1988, pp. 1927-1929.
2. Gibaldi M., Perrier D., "Pharmacokinetics," 2nd ed., Marcel Dekker Inc., New York, 1982.
3. USP Subcommittee on Biopharmaceutics, In Vitro In Vivo correlation for extended release oral dosage forms. Phar. Forum, July-Aug., 1988, pp. 4160-4161.
4. Skelley J. P., Amidon G. L., Barr W. H., Benet I. J., Carter J. E. Robinson J. R., Shah V. P., Yacobi A., J. Pharm. Sci., 79, 849-854 (1990).
5. "Guidance for the industry; Extended-release solid oral dosage forms: Development, evaluation and application of in vitro/in vivo correlations," U.S. Department of Health, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), September, 1997.
6. Hussein Z., Friedman M., Pharm. Res., 7, 1167-1171(1990).
7. Sirisuth N., Augsburger L. L., Edington N. D., Biopharm. Drug Dispos., 23, 1-8 (2002).
8. Dhawan S., Singh B., Garg S. K., Hota D., Dash R. J., Singla A. K., Sinha V. R., Clin. Pharmacokinet., 45, 317-324 (2006).
9. Eddington N. D., Marroum P., Uppoor R., Hessian A., Augsburger J., Pharm. Res., 15, 466-473 (1998).
10. Mahayni H., Rekhi G. S., Upoor R. S., Marroum P., Hussian A. S., Augsburger I. J., Edington N. D., J. Pharm. Sci., 89, 1354-1361 (2000).
11. Veng-Pedersen P., Gobburu J. V. S., Meyer M. C., Straugnn A. B., Biopharm. Drug Dispos., 21, 1-6 (2000).
12. Balan G., Timmins P., Green D. S., Marathe P. H., J. Pharm. Sci., 90, 1176-1185 (2001).
13. Dalton J. T., Straugnn A. B., Dickason D. A., Grandolfi G. P., Pharm. Res., 18, 1729-1734 (2001).
14. Roshdy M. N., Schnnare R. I., Sugita E. T., Zietz S., Schwartz J. B., Pharm. Dev. Techol., 7, 203-213 (2002).
15. U.S. Department of Health, Food and Drug Administration, "Dissolution Testing of Immediate Release Solid Oral Dosage Forms," August 1997.
16. Wagner J. G., "Biopharmaceutics and Relevant Pharmacokinetics," Drug Intelligence Publishers, Illinois, 1981.